Chemomab
CMMB
Chemomab (CMMB) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Oppenheimer | Maintained | Outperform | $25.00 from $10.00 | Aug 27, 2025 |
| Oppenheimer | Maintained | Outperform | $10.00 from $11.00 | May 16, 2025 |
| Maxim Group | Maintained | Buy | $7.00 from $4.00 | Feb 20, 2025 |
| Oppenheimer | Maintained | Outperform | $11.00 from $13.00 | Nov 15, 2024 |
| Maxim Group | Initiated Coverage | Buy | $4.00 | May 13, 2024 |
| Oppenheimer | Upgraded | Perform → Outperform | $6.00 | May 6, 2024 |
| Oppenheimer | Maintained | Perform | — | Mar 8, 2024 |
| Roth MKM | Maintained | Buy | $7.00 | Dec 19, 2023 |
| Roth MKM | Initiated Coverage | Buy | $7.00 | Oct 6, 2023 |
| Oppenheimer | Downgraded | Outperform → Perform | — | Jun 7, 2023 |
Frequently asked questions
What is the latest analyst rating on CMMB?
On Aug 27, 2025, Oppenheimer maintained Chemomab at Outperform with a price target of $25.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.